Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

182.69
-6.4600-3.42%
Post-market: 182.690.00000.00%19:36 EDT
Volume:827.04K
Turnover:152.69M
Market Cap:11.25B
PE:-31.28
High:189.26
Open:189.26
Low:182.55
Close:189.15
52wk High:198.00
52wk Low:95.49
Shares:61.56M
Float Shares:58.65M
Volume Ratio:0.83
T/O Rate:1.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8403
EPS(LYR):-5.8403
ROE:-8.47%
ROA:5.38%
PB:2.60
PE(LYR):-31.28

Loading ...

Is Jazz Pharmaceuticals (JAZZ) Still Attractive After 33% Share Price Gain This Year?

Simply Wall St.
·
Jan 11

Jazz Pharmaceuticals Names Chief Business Officer

MT Newswires Live
·
Jan 09

Press Release: Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

Dow Jones
·
Jan 09

RBC Trims Price Target on Jazz Pharmaceuticals to $191 From $194, Keeps Outperform Rating

MT Newswires Live
·
Jan 08

Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial

Benzinga_recent_news
·
Jan 08

Jazz Pharmaceuticals Reports Phase 3 Success for Ziihera in First-Line HER2+ Metastatic GEA

Reuters
·
Jan 07

Ziihera® (Zanidatamab-Hrii) Combinations Achieve Unprecedented Results in First-Line Her2+ Locally Advanced or Metastatic Gea Including More Than Two Years Median Overall Survival Benefit

THOMSON REUTERS
·
Jan 07

Jazz Pharmaceuticals Plc: Additional Planned Os Interim Analysis for Ziihera Plus Chemotherapy Is Currently Expected in Mid-2026

THOMSON REUTERS
·
Jan 07

Jazz Pharmaceuticals to Present Phase 3 Zanidatamab Trial Results at Investor Webcast

Reuters
·
Dec 18, 2025

Jazz Pharmaceuticals (JAZZ): Valuation Check After Positive Ziihera and Epidiolex Clinical Updates Boost Investor Interest

Simply Wall St.
·
Dec 15, 2025

Jazz Pharmaceuticals SVP Technical Operations Mary Elizabeth Henderson Reports Sale of Common Shares

Reuters
·
Dec 12, 2025

Jazz Pharmaceuticals Price Target Raised to $219.00/Share From $147.00 by Piper Sandler

Dow Jones
·
Dec 11, 2025

Jazz Pharmaceuticals SVP Chief Accounting Officer Patricia Carr Reports Disposal of Common Shares

Reuters
·
Dec 10, 2025

Jazz Pharmaceuticals Highlights New Epidiolex Data in Treatment-Resistant Epilepsies at AES 2025

Reuters
·
Dec 05, 2025

Jazz Pharmaceuticals Announces Positive Phase 3 Results for Ziihera in HER2-Positive Gastroesophageal Cancer

Reuters
·
Dec 03, 2025

Saniona AB Q3 2025 revenue surged to SEK 410.7 million, nearly 57 times higher

Reuters
·
Nov 27, 2025

Director Heather Ann McSharry Reports Disposal of Jazz Pharmaceuticals plc Common Shares

Reuters
·
Nov 25, 2025

Jazz Gains From Ziihera Data, Upside Seen as Priced In, UBS Says

MT Newswires Live
·
Nov 25, 2025

Jazz Pharmaceuticals Cut to Neutral From Buy by UBS

Dow Jones
·
Nov 24, 2025

Jazz Pharmaceuticals downgraded to Neutral from Buy at UBS

TIPRANKS
·
Nov 24, 2025